Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: adenocarcinoma versus squamous cell carcinoma

被引:3
|
作者
Soetandyo, Noorwati [1 ]
Hanafi, Arif Riswahyudi [2 ]
Agustini, Sri [1 ]
Sinulingga, Dian Triana [3 ]
机构
[1] Dharmais Natl Canc Ctr Hosp, Dept Hematol & Med Oncol, Jakarta, Indonesia
[2] Dharmais Natl Canc Ctr Hosp, Dept Pulmonol, Jakarta, Indonesia
[3] Dharmais Natl Canc Ctr Hosp, Jakarta, Indonesia
关键词
chemotherapy; histology; lung cancer; prognosis; BODY-MASS INDEX; SURVIVAL; EFFICACY; MORTALITY; OUTCOMES; SMOKING;
D O I
10.13181/mji.oa.203787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In Indonesia, lung cancer is one of the most prevalent solid cancer with the highest mortality rate. However, studies to identify prognostic factors associated with mortality are lacking. Thus, this study was aimed to determine the association of histological subtypes and prognosis of advanced stage non-small-cell lung cancer (NSCLC) patients receiving chemotherapy. METHODS This study focused on a retrospective cohort consisting of 60 patients with advanced stage NSCLC and treated with chemotherapy. Patients with NSCLC stage IIIB or stage IV, age >= 18 years, and good performance status were recruited. The outcomes were one-year mortality and treatment response. Gender, age, body mass index, staging, and performance status were evaluated. Chi-square and Fisher's exact tests were used. RESULTS Two common histological subtypes, adenocarcinoma (68.3%) and squamous cell carcinoma (31.7%), were observed among all subjects. Four patients (6.7%) died during one-year observation period. Mortality rate was higher in squamous cell carcinoma (10.5%) patients than in adenocarcinoma (4.9%). Underweight patients had higher risk of death (relative risk [RR] = 1.09, 95% confidence interval [CI] = 1.00-1.19) and disease progression (RR = 1.30, 95% CI = 1.12-1.51). In adenocarcinoma, metastasis was a risk for progressive disease (RR = 1.35, 95% CI = 1.09-1.66). In squamous cell carcinoma, men had a lower risk of disease progression (RR = 0.11, 95% CI = 0.03-0.41). CONCLUSIONS Squamous cell carcinoma had comparable one-year mortality and disease progression rate with adenocarcinoma type in advanced stage NSCLC. However, underweight patients had a higher risk of mortality and disease progression.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
  • [41] Chemotherapy for non-small-cell lung cancer
    Satoh, H
    Sekizawa, K
    LANCET, 2001, 358 (9289): : 1270 - 1271
  • [42] Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer
    Black, Candice C.
    Turk, Mary Jo
    Dragnev, Konstantin
    Rigas, James R.
    LUNG, 2013, 191 (03) : 265 - 270
  • [43] Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer
    Candice C. Black
    Mary Jo Turk
    Konstantin Dragnev
    James R. Rigas
    Lung, 2013, 191 : 265 - 270
  • [44] Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer
    Yueqiang Jiang
    Jun Zhang
    Jin Feng
    Yaping Lu
    Yuan Fan
    Ling Cheng
    Xin Liao
    Liya Hu
    Shiying Yu
    Tiejun Yin
    Journal of Genetics and Genomics, 2021, 48 (07) : 656 - 659
  • [45] Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    Jaskiewicz, Piotr
    Olszewski, Wlodzimierz
    Janowicz-Zebrowska, Anna
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    RESPIRATION, 2013, 85 (04) : 289 - 296
  • [46] Supportive Care Needs Trajectories in Patients With Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy: A Longitudinal Study
    Yen, Chun-Ju
    Hsu, Hsin-Tien
    Hsieh, Hsiu-Fen
    Chen, Ying-Ju
    Huang, Ming-Shyan
    Lin, Pei-Chao
    JOURNAL OF NURSING RESEARCH, 2023, 31 (03) : E275
  • [47] Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond
    Dubey, Sarita
    Siegfried, Jill M.
    Traynor, Anne M.
    LANCET ONCOLOGY, 2006, 7 (05): : 416 - 424
  • [48] Which Is the Optimal Immunotherapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer in Combination with Chemotherapy?
    Zhoum, H.
    Zhang, Y.
    Chen, G.
    Zhao, S.
    Liu, J.
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1059 - S1060
  • [49] Prognostic factors of advanced stage non-small-cell lung cancer
    Kwas, H.
    Guermazi, E.
    Khattab, A.
    Hrizi, C.
    Zendah, I.
    Ghedira, H.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2017, 73 (04) : 180 - 187
  • [50] Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    IMMUNOTHERAPY, 2023, 15 (14) : 1133 - 1142